This is the QA environment of the MD-SOAR platform. It is for TESTING PURPOSES ONLY. Navigate to https://mdsoar.org to access the latest open access research from MD-SOAR institutions.
QA Environment
 

Dynamics of biosimilar uptake in emerging markets

Simple item page
dc.contributor.authorChhabra, Hemlata
dc.contributor.authorMouslim, Morgane
dc.contributor.authorKashiramka, Smita
dc.contributor.authorRathore, Anurag S
dc.date.accessioned2022-06-24T14:30:12Z
dc.date.available2022-06-24T14:30:12Z
dc.date.issued2022-05-22
dc.description.abstractIntroduction Globally, biosimilars are expected to play a key role in lowering healthcare costs and providing increased patient access to biological therapies. Given this, and in line with the European Union and World Health Organization, many emerging nations have adapted and established biosimilar regulatory guidelines. Emerging nations present a lucrative market for biosimilar development and commercialization, yet they also pose unique challenges. A thorough understanding of the unique attributes of emerging markets in relation to biosimilars is needed to promote their successful uptake in low- and middle-income countries. Areas covered This article highlights the opportunities and challenges that emerging markets represent in terms of biosimilar uptake. A comprehensive analysis of biosimilar uptake in European countries, where biosimilars have gained significant market share, was carried out to identify policies that can enhance market penetration in emerging nations. Expert opinion Implementation of pricing and procurement policies, as well as provider and patient confidence in biosimilar efficacy, are key factors in their uptake. Due to the high cost of biosimilar development, incentivizing domestic companies with the biosimilar manufacturing capability to produce these drugs will be helpful in ensuring a sustainable biosimilar market and a steady supply chain.en_US
dc.description.sponsorshipThis paper was funded by the Department of Biotechnology, Ministry of Science and Technology, India (number BT/COE/34/SP15097/2015).en_US
dc.description.urihttps://www.tandfonline.com/doi/abs/10.1080/14712598.2022.2076557en_US
dc.format.extent33 pagesen_US
dc.genrejournal articlesen_US
dc.genrepostprintsen_US
dc.identifierdoi:10.13016/m24cut-yuna
dc.identifier.citationHemlata Chhabra, Morgane C Mouslim, Smita Kashiramka & Anurag S Rathore (2022) Dynamics of biosimilar uptake in emerging markets, Expert Opinion on Biological Therapy, 22:6, 679-688, DOI: 10.1080/14712598.2022.2076557en_US
dc.identifier.urihttps://doi.org/10.1080/14712598.2022.2076557
dc.identifier.urihttp://hdl.handle.net/11603/25034
dc.language.isoen_USen_US
dc.publisherTaylor & Francisen_US
dc.relation.isAvailableAthe University of Maryland, Baltimore County (UMBC)
dc.relation.ispartofUMBC Staff Collection
dc.relation.ispartofA. All Hilltop Institute (UMBC) Works
dc.relation.ispartofJ. Other (The Hilltop Institute, UMBC)
dc.rightsThis is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Biological Therapy on 22 May 2022, available online: http://www.tandfonline.com/10.1080/14712598.2022.2076557.en_US
dc.rightsAccess to this item will begin on date Nov. 9, 2023
dc.titleDynamics of biosimilar uptake in emerging marketsen_US
dc.typeTexten_US
dcterms.creatorhttps://orcid.org/0000-0002-6999-7588en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dynamics of biosimilar uptake in emerging markets.pdf
Size:
950.03 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.56 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

UMBC Staff Collection
A. All Hilltop Institute (UMBC) Works
J. Other (The Hilltop Institute, UMBC)